Literature DB >> 10651183

An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.

K Niki1, M Sugawara, S Tanino, K Iwade, S Hosoda, H Kasanuki.   

Abstract

A theoretical equation was derived based on the time-varying elastance model to predict theoretically the relationship between the delay in the onset of left ventricular outflow obstruction and the reduction in peak left ventricular pressure (LVP) caused by treatment in hypertrophic obstructive cardiomyopathy (HOCM). ECG, LVP, and other hemodynamic parameters were measured during catheterization at a constant heart rate with atrial pacing in 16 patients with HOCM before and after intravenous administration of disopyramide (1 mg/kg). After disopyramide administration, the duration between the R wave of the ECG and the onset of obstruction (T1) was prolonged significantly (from 117 +/- 30 to 155 +/- 32 ms, P < 0.0001), and peak LVP was reduced significantly (from 222 +/- 42 to 177 +/- 39 mmHg, P < 0.0001). The relation between the prolongation of T1 and the percent reduction in peak LVP was predicted well by the theoretical equation (coefficient of determination R2 = 0.926). Our model simplifies the therapeutic strategy for reducing the left ventricular outflow pressure gradient in patients with HOCM, which is to delay the time of onset of obstruction by some methods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10651183     DOI: 10.1007/bf02481746

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  29 in total

Review 1.  Relaxation and diastole of the heart.

Authors:  D L Brutsaert; S U Sys
Journal:  Physiol Rev       Date:  1989-10       Impact factor: 37.312

2.  Effects of disopyramide on repolarisation and intraventricular conduction in man.

Authors:  K Endresen; J P Amlie; K Forfang
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio.

Authors:  H Suga; K Sagawa; A A Shoukas
Journal:  Circ Res       Date:  1973-03       Impact factor: 17.367

Review 4.  Medical and surgical therapy of hypertrophic cardiomyopathy.

Authors:  R O Bonow; B J Maron; M B Leon; R O Cannon; S E Epstein
Journal:  Cardiovasc Clin       Date:  1988

5.  Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient.

Authors:  C Pollick; H Rakowski; E D Wigle
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

6.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.

Authors:  C Pollick
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

7.  Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.

Authors:  W J Duncan; M J Tyrrell; B B Bharadwaj
Journal:  Can J Cardiol       Date:  1991-03       Impact factor: 5.223

8.  Haemodynamic effects of disopyramide in patients after open-heart surgery.

Authors:  N Naqvi; D S Thompson; W E Morgan; B T Williams; D J Coltart
Journal:  Br Heart J       Date:  1979-11

9.  Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy.

Authors:  K McDonald; E McWilliams; B O'Keeffe; B Maurer
Journal:  Eur Heart J       Date:  1988-08       Impact factor: 29.983

10.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.

Authors:  X Jeanrenaud; J J Goy; L Kappenberger
Journal:  Lancet       Date:  1992-05-30       Impact factor: 79.321

View more
  1 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.